A novel BRCA2 mutation that segregates with breast and prostate cancer in a Spanish family.

abstract：:The purpose of this study is to compare immunohistochemistry (IHC) and cytosol-based assays for determination of estrogen receptor (ER) and prediction of response to adjuvant tamoxifen treatment in postmenopausal women with early-stage invasive breast cancer. The Stockholm Breast Cancer Study Group conducted a randomi...

journal_title：Breast cancer research and treatment

authors： Khoshnoud MR,Löfdahl B,Fohlin H,Fornander T,Stål O,Skoog L,Bergh J,Nordenskjöld B

更新日期：2011-04-01 00:00:00

abstract：BACKGROUND:After experiencing a distant recurrence, breast cancer patients have a poor prognosis; fewer than 5% survive for ten or more years. However, the time to death is highly variable, ranging from a few months to many years. The purpose of this study is to identify, in a large hospital-based series of patients wi...

journal_title：Breast cancer research and treatment

authors： Sopik V,Sun P,Narod SA

更新日期：2019-01-01 00:00:00

abstract：:Aromatase inhibitors (AIs) are used for treatment of estrogen receptor α (ER)-positive breast cancer; however, resistance is a major obstacle for optimal outcome. This preclinical study aimed at identifying potential new treatment targets in AI-resistant breast cancer cells. Parental MCF-7 breast cancer cells and four...

journal_title：Breast cancer research and treatment

authors： Hole S,Pedersen AM,Lykkesfeldt AE,Yde CW

更新日期：2015-02-01 00:00:00

abstract：BACKGROUND:The anatomy of the nipple has become clinically relevant. Diagnostic techniques access the breast through nipple ducts and surgeons offer nipple-sparing mastectomy. There is variation in the number of ducts reported and little is known about the spatial location of ducts, their size, and their relationship t...

journal_title：Breast cancer research and treatment

authors： Rusby JE,Brachtel EF,Michaelson JS,Koerner FC,Smith BL

更新日期：2007-12-01 00:00:00

abstract：:Identifying risk factors for lymphedema in patients treated for breast cancer has become increasingly important, given the current lack of standardization surrounding diagnosis and treatment. Reports on the association of body mass index (BMI) and weight change with lymphedema risk are conflicting. We sought to examin...

journal_title：Breast cancer research and treatment

authors： Jammallo LS,Miller CL,Singer M,Horick NK,Skolny MN,Specht MC,O'Toole J,Taghian AG

更新日期：2013-11-01 00:00:00

abstract：:Many genetic abnormalities disclosed even in somatic cells like peripheral blood lymphocytes may mark footprint(s) of malignancy(ies). The present cytogenetic study on peripheral blood lymphocytes of sporadic breast cancer patients (n = 20) and their first degree relatives (n = 39) reports abnormalities of chromosomes...

journal_title：Breast cancer research and treatment

authors： Trivedi AH,Roy SK,Bhachech SH,Patel RK,Dalal AA,Bhatavdekar JM,Patel DD

更新日期：1998-03-01 00:00:00

abstract：PURPOSE:Previous work found that lower BMI is associated with a pathologic complete response (pCR) following neoadjuvant chemotherapy for breast cancer. Relative dose intensity (RDI) of chemotherapy is an important marker of treatment tolerability. We hypothesized that patients with low BMI would have higher RDI than p...

journal_title：Breast cancer research and treatment

authors： Usiskin I,Li F,Irwin ML,Cartmel B,Sanft T

更新日期：2020-10-30 00:00:00

abstract：:Oestrogen receptor (ER) negative breast cancers are more likely to achieve a pathological complete response (pCR) to neoadjuvant chemotherapy compared to those with ER positive tumours. ER positive tumours exhibit low proliferation and ER negative cancers high proliferation. The aim of this study was to determine to w...

journal_title：Breast cancer research and treatment

authors： Jones RL,Salter J,A'Hern R,Nerurkar A,Parton M,Reis-Filho JS,Smith IE,Dowsett M

更新日期：2010-01-01 00:00:00

abstract：PURPOSE:The stage-specific survival of young breast cancer patients has improved, likely due to diagnostic and treatment advances. We addressed whether survival improvements have reached all socioeconomic groups in a country with universal health care and national treatment guidelines. METHODS:Using Norwegian registry...

journal_title：Breast cancer research and treatment

authors： Trewin CB,Johansson ALV,Hjerkind KV,Strand BH,Kiserud CE,Ursin G

更新日期：2020-07-01 00:00:00

abstract：PURPOSE:Existing high-risk clinic models focus on patients with known risk factors, potentially missing many high-risk patients. Here we describe our experience implementing universal risk assessment in an ambulatory breast center. METHODS:Since May 2017, all breast center patients completed a customized intake survey...

journal_title：Breast cancer research and treatment

authors： Weiss A,Grossmith S,Cutts D,Mikami SA,Suskin JA,Graichen MK,Rojas NA,Pace LE,Joyce E,Rhei E,Scheib R,Bychkovsky B,Garber JE,Morganstern D,King TA

更新日期：2019-05-01 00:00:00

abstract：:WWOX is a cancer gene, spanning the common chromosomal fragile site 16D. Genomic and expression aberrations affecting this gene and locus are common in various neoplasias including breast cancer. The aim of the present study was to evaluate the relationship between WWOX expression at the protein level with respect to ...

journal_title：Breast cancer research and treatment

authors： Nunez MI,Ludes-Meyers J,Abba MC,Kil H,Abbey NW,Page RE,Sahin A,Klein-Szanto AJ,Aldaz CM

更新日期：2005-01-01 00:00:00

abstract：:Mutations in breast cancer susceptibility genes, BRCA1 and BRCA2 account for more than 80% of hereditary breast and ovarian cancers. p53 tumor suppressor gene that controls cellular growth and differentiation is also known to be mutated in more than 50% of human cancers including breast cancer. We have carried out a s...

journal_title：Breast cancer research and treatment

authors： Hedau S,Jain N,Husain SA,Mandal AK,Ray G,Shahid M,Kant R,Gupta V,Shukla NK,Deo SS,Das BC

更新日期：2004-11-01 00:00:00

abstract：:While several risk factors for breast cancer have been identified, studies have not consistently shown whether these factors operate more strongly at certain ages or for just pre- or postmenopausal women. We evaluated whether risk factors for breast cancer differ according to age or menopausal status. Data from five p...

journal_title：Breast cancer research and treatment

authors： Trentham-Dietz A,Sprague BL,Hampton JM,Miglioretti DL,Nelson HD,Titus LJ,Egan KM,Remington PL,Newcomb PA

更新日期：2014-05-01 00:00:00

abstract：:One of the most efficacious primary therapies in HER2-positive breast cancer was published by the M.D. Anderson group in 2005. This randomized trial evaluated the addition of trastuzumab to a taxane-anthracycline based chemotherapy. Despite largely significant differences in pathological complete response (pCR) in the...

journal_title：Breast cancer research and treatment

authors： Pernas S,Gil-Gil M,de Olza MO,Gumà A,Climent F,Petit A,Pla MJ,García-Tejedor A,López-Ojeda A,Falo C,Fernandez-Otega A,Mesia C,Pérez-Martin FJ,Urruticoechea A,Germà JR

更新日期：2012-08-01 00:00:00

abstract：:This prospective study assessed the endometrial effects of fulvestrant, a pure estrogen-receptor antagonist, in postmenopausal women with breast cancer. This single-center study enrolled postmenopausal patients who had an intact uterus at baseline with progressive metastatic breast cancer on tamoxifen followed by an o...

journal_title：Breast cancer research and treatment

authors： Morales L,Neven P,Timmerman D,Wildiers H,Konstantinovic ML,Christiaens MR,Tan PN,Paridaens R

更新日期：2009-09-01 00:00:00

abstract：UNLABELLED:Taxanes and anthracyclines improve the outcome of early breast cancer, although the benefit is limited to a small proportion of patients and are toxic. We prospectively looked for predictors of response to these drugs. EXPERIMENTAL DESIGN:Four cycles of doxorubicin (75 mg/m²) or docetaxel (100 mg/m²) were c...

journal_title：Breast cancer research and treatment

authors： Martin M,Romero A,Cheang MC,López García-Asenjo JA,García-Saenz JA,Oliva B,Román JM,He X,Casado A,de la Torre J,Furio V,Puente J,Caldés T,Vidart JA,Lopez-Tarruella S,Diaz-Rubio E,Perou CM

更新日期：2011-07-01 00:00:00

abstract：BACKGROUND:TOP2A gene encodes topoisomerase II alpha, the direct molecular target of anthracyclines. This gene is frequently coamplified with HER2. The aims of this study were to analyse the pattern of TOP2A amplification and protein expression in relation to the molecular subgroups of breast cancers; and to define the...

journal_title：Breast cancer research and treatment

authors： Arriola E,Rodriguez-Pinilla SM,Lambros MB,Jones RL,James M,Savage K,Smith IE,Dowsett M,Reis-Filho JS

更新日期：2007-12-01 00:00:00

abstract：:Anthracyclines are among the most powerful antineoplastic drugs available for breast cancer treatment. Although HER2 amplification has been postulated to predict anthracycline benefit, numerous reports have demonstrated that HER2/TOP2A co-amplification is the clinically useful predictive marker of response to anthracy...

journal_title：Breast cancer research and treatment

authors： García-Caballero T,Prieto O,Vázquez-Boquete A,Gude F,Viaño P,Otero M,Curiel T,Fernández-Rodríguez B,Parrado C,Fraga M,Antúnez JR

更新日期：2014-01-01 00:00:00

abstract：:Previous studies on the association between mammography screening and stage at breast cancer (BC) diagnosis have limitations because they did not analyze persistence with mammography screening and did not distinguish screening from diagnostic mammograms. The objective of this study is to determine the association betw...

journal_title：Breast cancer research and treatment

authors： Vyas A,Madhavan S,Sambamoorthi U

更新日期：2014-12-01 00:00:00

abstract：:Methylthioadenosine (MTA) phosphorylase activity was measured in 47 biopsies from primary breast cancers (n = 34) and metastatic tumors (n = 13). Most specimens were also evaluated by DNA flow cytometry and determination of estrogen and progesterone receptor contents. Median MTA phosphorylase activity was 317 pmol/mg ...

journal_title：Breast cancer research and treatment

authors： Smaaland R,Schanche JS,Kvinnsland S,Høstmark J,Ueland PM

更新日期：1987-01-01 00:00:00

abstract：PURPOSE:Compared to breast cancer risk genes such as BRCA2, ATM, PALB2, and NBN, no defined phenotype is currently associated with biallelic pathogenic variants (PVs) in CHEK2. This study compared the prevalence of breast and other cancers in women with monoallelic and biallelic CHEK2 PVs. METHODS:CHEK2 PV carriers we...

journal_title：Breast cancer research and treatment

authors： Rainville I,Hatcher S,Rosenthal E,Larson K,Bernhisel R,Meek S,Gorringe H,Mundt E,Manley S

更新日期：2020-04-01 00:00:00

abstract：:To assess the impact of patient-provider communication on adherence to tamoxifen (TAM) and aromatase inhibitors (AIs) 36 months after breast cancer (BC) diagnosis in a low-income population of women. California statewide surveys were conducted among 921 low-income women with BC at 6, 18, and 36 months after BC diagnos...

journal_title：Breast cancer research and treatment

authors： Liu Y,Malin JL,Diamant AL,Thind A,Maly RC

更新日期：2013-02-01 00:00:00

abstract：:The Breast Cancer Family Registry is a resource for interdisciplinary and translational studies of the genetic epidemiology of breast cancer. This resource is available to researchers worldwide for collaborative studies. Herein, we report the results of testing for germline mutations in BRCA1 and BRCA2. We have tested...

journal_title：Breast cancer research and treatment

authors： Neuhausen SL,Ozcelik H,Southey MC,John EM,Godwin AK,Chung W,Iriondo-Perez J,Miron A,Santella RM,Whittemore A,Andrulis IL,Buys SS,Daly MB,Hopper JL,Seminara D,Senie RT,Terry MB,Breast Cancer Family Registry.

更新日期：2009-07-01 00:00:00

abstract：PURPOSE:To examine whether depression, anxiety disorder, and their co-occurrence would increase the risk of mortality in patients with breast cancer, and whether antidepressant treatment would reduce the same. METHODS:Data were retrieved from the database of the Korean National Health Insurance Service. Of 145,251 pat...

journal_title：Breast cancer research and treatment

authors： Shim EJ,Lee JW,Cho J,Jung HK,Kim NH,Lee JE,Min J,Noh WC,Park SH,Kim YS

更新日期：2020-01-01 00:00:00

abstract：:Familial aggregations of breast/ovarian cancer cases frequently depend on BRCA1/2 pathogenic mutations. Here we counselled 120 Italian breast/ovarian cancer families and selected 73 probands for BRCA1/2 mutation screening. Through this analysis we defined the prevalence of BRCA1/2 pathogenic mutations occurring in Ita...

journal_title：Breast cancer research and treatment

authors： Giannini G,Capalbo C,Ristori E,Ricevuto E,Sidoni T,Buffone A,Cortesi E,Marchetti P,Scambia G,Tomao S,Rinaldi C,Zani M,Ferraro S,Frati L,Screpanti I,Gulino A

更新日期：2006-11-01 00:00:00

abstract：:The epidermal growth factor (EGF) is one of several growth factors involved in normal breast epithelial development and tumor proliferation. EGF and EGF-like peptide TGF alpha bind and activate the same membrane receptor protein. This receptor (EGF-R) has been recently studied in breast tumor biopsies and its detectab...

journal_title：Breast cancer research and treatment

authors： Falette N,Lefebvre MF,Meggouh F,Eynard M,Garin E,Saez S

更新日期：1992-03-01 00:00:00

abstract：PURPOSE:To investigate whether treatment (surgery, radiation therapy, and endocrine therapy) contributes to racial disparities in outcomes of ductal carcinoma in situ (DCIS). PATIENTS AND METHODS:The analysis included 8184 non-Hispanic White and 954 non-Hispanic Black women diagnosed with DCIS between 1996 and 2011 an...

journal_title：Breast cancer research and treatment

authors： Madubata CC,Liu Y,Goodman MS,Yun S,Yu J,Lian M,Colditz GA

更新日期：2016-12-01 00:00:00

abstract：:Screening of a breast cancer cDNA library from SKBR3 human breast cancer cells by SEREX (serological analysis of cDNA expression library) using a preselected serum from a breast cancer patient revealed 13 genes, two of which, INT-MI-1 and INT-MI-2, encode novel gene products, while the remaining 11 genes and their pro...

journal_title：Breast cancer research and treatment

authors： Forti S,Scanlan MJ,Invernizzi A,Castiglioni F,Pupa S,Agresti R,Fontanelli R,Morelli D,Old LJ,Pupa SM,Ménard S

更新日期：2002-06-01 00:00:00

abstract：:Tumour hypoxia, being widespread in solid tumours, is related to an increased risk of invasion and metastasis as well as to resistance to chemotherapy and radiotherapy. Hypoxia-inducible factor-1alpha (HIF-1alpha) has emerged as the key regulator of the cellular response to hypoxia. In primary breast cancers, HIF-1alp...

journal_title：Breast cancer research and treatment

authors： Smollich M,Götte M,Kersting C,Fischgräbe J,Kiesel L,Wülfing P

更新日期：2008-03-01 00:00:00

abstract：PURPOSE:Triple-negative breast cancers (TNBC) are aggressive tumours that exhibit abundant lymphoid infiltrates which modulate tumour behaviour. Recent findings suggest that TNBC with higher densities of plasma cells are associated with a favourable prognosis, and tertiary lymphoid structures (TLS) have prognostic sign...

journal_title：Breast cancer research and treatment

authors： Seow DYB,Yeong JPS,Lim JX,Chia N,Lim JCT,Ong CCH,Tan PH,Iqbal J

更新日期：2020-04-01 00:00:00